# CAR-T cell therapy: current limitations and potential strategies

“CAR-T cell therapy: current limitations and potential strategies” (2021), by Robert C. Sterner et al. Medicine research paper. Original abstract below, unchanged. A free PDF is available.

- Authors: Robert C. Sterner, Rosalie M. Sterner, Rosalie M. Sterner, Rosalie M. Sterner
- Published: April 6, 2021
- Field: Medicine
- DOI: https://doi.org/10.1038/s41408-021-00459-7
- Free PDF: https://www.nature.com/articles/s41408-021-00459-7.pdf

## Abstract

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.

Canonical page: https://nerdi.pages.dev/paper/W3148729173
Read three real papers a day in Nerdi (iPhone): https://apps.apple.com/app/apple-store/id6813826387?pt=128757794&ct=web-paper&mt=8